Scarica l'app Stockscreener
5.12
0.58%
-0.03
Dopo l'orario di chiusura:
5.30
0.18
+3.52%
Precedente Chiudi:
$5.15
Aprire:
$5.15
Volume 24 ore:
382.02K
Relative Volume:
1.66
Capitalizzazione di mercato:
$107.13M
Reddito:
-
Utile/perdita netta:
$-14.88M
Rapporto P/E:
-5.2245
EPS:
-0.98
Flusso di cassa netto:
$-10.29M
1 W Prestazione:
-11.72%
1M Prestazione:
-15.65%
6M Prestazione:
-14.67%
1 anno Prestazione:
-15.65%
Intervallo 1D:
$4.99
$5.40
Intervallo di 1 settimana:
$4.99
$5.96
Portata 52W:
$4.65
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Confronta COYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.12 | 107.76M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Lake Street | Buy |
| 2024-12-04 | Iniziato | D. Boral Capital | Buy |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
Is Coya Therapeutics Inc. stock a safe buy before earnings2025 AllTime Highs & Verified High Yield Trade Plans - ulpravda.ru
Is Coya Therapeutics Inc. stock a bargain at current levels2025 Year in Review & High Accuracy Swing Entry Alerts - ulpravda.ru
Is Coya Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - ulpravda.ru
Is Coya Therapeutics Inc. stock cheap compared to fundamentals2025 Key Lessons & Technical Pattern Based Buy Signals - ulpravda.ru
Aug Intraday: How Coya Therapeutics Inc. stock reacts to job market dataJuly 2025 Price Swings & Comprehensive Market Scan Reports - ulpravda.ru
Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - MarketScreener
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating - TipRanks
COYA: Analyst Maintains Buy Rating and $15 Target Price | COYA S - GuruFocus
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data - TipRanks
Coya Therapeutics Announces Positive Study Results for FTD Treatment - TradingView — Track All Markets
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com Canada
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - The Joplin Globe
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal Dementia - MarketScreener
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - moha.gov.vn
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
Moving Averages: Why retail investors pile into Coya Therapeutics Inc. stockEarnings Recap Report & Reliable Entry Point Alerts - Улправда
Why retail investors pile into Coya Therapeutics Inc. stock2025 Trading Volume Trends & Low Volatility Stock Recommendations - Улправда
Analyst Upgrade: Is Coya Therapeutics Inc. stock a bargain at current levels2025 Volatility Report & Capital Protection Trading Alerts - DonanımHaber
Can Coya Therapeutics Inc. stock maintain operating marginsJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Coya Therapeutics Receives $4.2M Milestone Payment - TipRanks
Coya Therapeutics Receives Milestone Payment for ALS Trial - TradingView — Track All Markets
Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment - Stock Titan
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Average Price Target from Brokerages - Defense World
Coya Therapeutics receives $4.2M milestone payment - MSN
Coya Therapeutics Earnings Notes - Trefis
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Responsive Playbooks and the COYA Inflection - Stock Traders Daily
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock By Investing.com - Investing.com Canada
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - BioSpace
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302 - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als - marketscreener.com
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space - BioSpace
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):